Mechanism of subclinical hypothyroidism accelerating endothelial dysfunction (Review)

Experimental and Therapeutic Medicine

Volumn 9, Issue 1, 2015, Pages 3-10

  Lu, Ming ^a,b   Yang, Chong Bo ^a,b   Gao, Ling ^a,b   Zhao, Jia Jun ^a,b  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^b Shandong Academy of Clinical Medicine   (China)

Author keywords

Chronic inflammation; Endothelial dysfunction; L thyroxine replacement therapy; Lipid profile; Oxidative stress; Subclinical hypothyroidism; Thyroid stimulating hormone receptor

Indexed keywords

3 NITROTYROSINE; ASCORBIC ACID; C REACTIVE PROTEIN; CARBONYL DERIVATIVE; CAVEOLIN 1; DIMETHYLARGININASE; GLYCERYL TRINITRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; LEVOTHYROXINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; N (G), N (G) DIMETHYLARGININE; NICOTINAMIDE ADENINE DINUCLEOTIDE; NITRIC OXIDE SYNTHASE; PROPYLTHIOURACIL; PROSTACYCLIN; REACTIVE OXYGEN METABOLITE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; THYROTROPIN RECEPTOR; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHRONIC INFLAMMATION; DNA POLYMORPHISM; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; INFLAMMATION; INSULIN RESISTANCE; META ANALYSIS (TOPIC); OXIDATIVE STRESS; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SUBCLINICAL HYPOTHYROIDISM; SUBSTITUTION THERAPY; THYROID CARCINOMA; UPREGULATION; VASODILATATION;

EID: 84919429670     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2014.2037     Document Type: Review

References (76)

1. Surks MI, Ortiz E, Daniels GH, et al: Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA 291: 228-238, 2004.
2. Cooper DS and Biondi B: Subclinical thyroid disease. Lancet 379: 1142-1154, 2012.
3. Boelaert K: Thyroid dysfunction in the elderly. Nat Rev Endocrinol 9: 194-204, 2013.
4. Hak AE, Pols HA, Visser TJ, Drexhage HA, Hofman A and Witteman JC: Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam study. Ann Intern Med 132: 270-278, 2000.
5. Rodondi N, Newman AB, Vittinghoff E, et al: Subclinical hypothyroidism and the risk of heart failure, other cardiovascular events, and death. Arch Intern Med 165: 2460-2466, 2005.
6. Walsh JP, Bremner AP, Bulsara MK, et al: Subclinical thyroid dysfunction as a risk factor for cardiovascular disease. Arch Intern Med 165: 2467-2472, 2005.
7. Razvi S, Weaver JU, Vanderpump MP and Pearce SH: The incidence of ischemic heart disease and mortality in people with subclinical hypothyroidism: reanalysis of the Whickham Survey cohort. J Clin Endocrinol Metab 95: 1734-1740, 2010.
8. Rodondi N, den Elzen WP, Bauer DC, et al: Subclinical hypo-thyroidism and the risk of coronary heart disease and mortality. JAMA 304: 1365-1374, 2010.
9. Tseng FY, Lin WY, Lin CC, et al: Subclinical hypothyroidism is associated with increased risk for all-cause and cardiovascular mortality in adults. J Am Coll Cardiol 60: 730-737, 2012.
10. Gencer B, Collet TH, Virgini V, Auer R and Rodondi N: Subclinical thyroid dysfunction and cardiovascular outcomes among prospective cohort studies. Endocr Metab Immune Disord Drug Targets 13: 4-12, 2013.
11. Lusis AJ: Atherosclerosis. Nature 407: 233-241, 2000.
12. Galkina E and Ley K: Immune and inflammatory mechanisms of atherosclerosis. Ann Rev Immunol 27: 165, 2009.
13. Libby P, Ridker PM and Hansson GK: Progress and challenges in translating the biology of atherosclerosis. Nature 473: 317-325, 2011.
14. Bonetti PO, Lerman LO and Lerman A: Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol 23: 168-175, 2003.
15. Makino A and Kamata K: Possible modulation by endothelin-1, nitric oxide, prostaglandin I2 and thromboxane A2 of vasoconstriction induced by an α-agonist in mesenteric arterial bed from diabetic rats. Diabetologia 41: 1410-1418, 1998.
16. Beckman JS and Koppenol WH: Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and the ugly. Am J Physiol 40: C1424, 1996.
17. Alderton WK, Cooper CE and Knowles RG: Nitric oxide synthases: structure, function and inhibition. Biochem J 357: 593-615, 2001.
18. Hollenberg SM and Cinel I: Bench-to-bedside review: nitric oxide in critical illness-update 2008. Crit Care 13: 218, 2009.
19. Esper RJ, Nordaby RA, Vilariño JO, Paragano A, Cacharrón JL and Machado RA: Endothelial dysfunction: a comprehensive appraisal. Cardiovasc Diabetol 5: 4-22, 2006.
20. Mudau M, Genis A, Lochner A and Strijdom H: Endothelial dysfunction: the early predictor of atherosclerosis. Cardiovasc J Afr 23: 222-231, 2012.
21. Frank PG, Pavlides S and Lisanti MP: Caveolae and transcytosis in endothelial cells: role in atherosclerosis. Cell Tissue Res 335: 41-47, 2009.
22. Sowa G: Caveolae, caveolins, cavins, and endothelial cell function: new insights. Front Physiol 2: 120, 2012.
23. Widlansky ME, Gokce N, Keaney JF, Jr. and Vita JA: The clinical implications of endothelial dysfunction. J Am Coll Cardiol 42: 1149-1160, 2003.
24. Kim VN: MicroRNA biogenesis: coordinated cropping and dicing. Nat Rev Mol Cell Biol 6: 376-385, 2005.
25. Sun X, Belkin N and Feinberg MW: Endothelial microRNAs and atherosclerosis. Curr Atheroscler Rep 15: 1-13, 2013.
26. Loyer X, Potteaux S, Vion AC, et al: Inhibition of MicroRNA-92a Prevents Endothelial Dysfunction and Atherosclerosis in Mice. Circ Res 114: 434-443, 2014.
27. Menghini R, Casagrande V and Federici M: MicroRNAs in endothelial senescence and atherosclerosis. J Cardiovasc Transl Res 6: 924-930, 2013.
28. Zhang X, Shao S, Geng H, et al: Expression profiles of six circulating microRNAs critical to atherosclerosis in patients with subclinical hypothyroidism: a clinical study. J Clin Endocrinol Metab 99: E766-774, 2014.
29. Turemen EE, Cetinarslan B, Sahin T, Canturk Z and Tarkun I: Endothelial dysfunction and low grade chronic inflammation in subclinical hypothyroidism due to autoimmune thyroiditis. Endocr J 58: 349-354, 2011.
30. Dardano A, Ghiadoni L, Plantinga Y, et al: Recombinant human thyrotropin reduces endothelium-dependent vasodilation in patients monitored for differentiated thyroid carcinoma. J Clin Endocrinol Metab 91: 4175-4178, 2006.
31. Gao N, Zhang W, Zhang YZ, Yang Q and Chen SH: Carotid intima-media thickness in patients with subclinical hypothyroidism: a meta-analysis. Atherosclerosis 227: 18-25, 2013.
32. Balzan S, Del Carratore R, Nicolini G, et al: Proangiogenic effect of TSH in human microvascular endothelial cells through its membrane receptor. J Clin Endocrinol Metab 97: 1763-1770, 2012.
33. Tian L, Zhang L, Liu J, Guo T, Gao C and Ni J: Effects of TSH on the function of human umbilical vein endothelial cells. J Mol Endocrinol 52: 215-222, 2014.
34. Wang Y, Zhong J, Wei W, et al: Developmental iodine deficiency and hypothyroidism impair neural development, upregulate caveolin-1, and downregulate synaptotagmin-1 in the rat cerebellum. Biol Trace Elem Res 144: 1039-1049, 2011.
35. Gong J, Dong J, Wang Y, et al: Developmental iodine deficiency and hypothyroidism impair neural development, up-regulate caveolin-1 and down-regulate synaptophysin in rat hippocampus. J Neuroendocrinology 22: 129-139, 2010.
36. Sarati LI, Martinez CR, Artés N, et al: Hypothyroidism: age-related influence on cardiovascular nitric oxide system in rats. Metabolism 61: 1301-1311, 2012.
37. Latif R, Ando T and Davies TF: Lipid rafts are triage centers for multimeric and monomeric thyrotropin receptor regulation. Endocrinology 148: 3164-3175, 2007.
38. Ito A, Tsao PS, Adimoolam S, Kimoto M, Ogawa T and Cooke JP: Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. Circulation 99: 3092-3095, 1999.
39. Nofer J-R, van der Giet M, Tölle M, et al: HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J Clin Invest 113: 569-581, 2004.
40. Lai Y, Wang J, Jiang F, et al: The relationship between serum thyrotropin and components of metabolic syndrome. Endocr J 58: 23-30, 2011.
41. Åsvold BO, Vatten LJ, Nilsen TI and Bjøro T: The association between TSH within the reference range and serum lipid concentrations in a population-based study. The HUNT Study. Eur J Endocrinol 156: 181-186, 2007.
42. Geng H, Zhang X, Wang C, et al: Even mildly elevated TSH is associated with an atherogenic lipid profile in postmenopausal women with subclinical hypothyroidism. Endocr Res: Mar 28, 2014 (Epub ahead of print).
43. Xiang GD, Xiang LW, He HL and Zhao LS: Postprandial lipaemia suppresses endothelium-dependent arterial dilation in patients with hypothyroidism. Endocrine 42: 391-398, 2012.
44. Tian L, Song Y, Xing M, et al: A novel role for thyroid-stimulating hormone: Up-regulation of hepatic 3-hydroxy-3-methy l-glutaryl-coenzyme a reductase expression through the cyclic adenosine monophosphate/protein kinase A/cyclic adenosine monophosphate-responsive element binding protein pathway. Hepatology 52: 1401-1409, 2010.
45. Taddei S, Caraccio N, Virdis A, et al: Low-grade systemic inflammation causes endothelial dysfunction in patients with Hashimoto's thyroiditis. J Clin Endocrinol Metab 91: 5076-5082, 2006.
46. Ridker PM, Rifai N, Stampfer MJ and Hennekens CH: Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 101: 1767-1772, 2000.
47. Antunes TT, Gagnon A, Bell A and Sorisky A: Thyroid-stimulating hormone stimulates interleukin-6 release from 3T3-L1 adipocytes through a cAMP-protein kinase A pathway. Obes Res 13: 2066-2071, 2005.
48. Zhang C, Xu X, Potter BJ, et al: TNF-alpha contributes to endothelial dysfunction in ischemia/reperfusion injury. Arterioscler Thromb Vasc Biol 26: 475-480, 2006.
49. Whetsell M, Bagriacik EU, Seetharamaiah GS, Prabhakar BS and Klein JR: Neuroendocrine-induced synthesis of bone marrow-derived cytokines with inflammatory immunomodu lating properties. Cell Immunol 192: 159-166, 1999.
50. Christ-Crain M, Meier C, Guglielmetti M, et al: Elevated C-reactive protein and homocysteine values: cardiovascular risk factors in hypothyroidism? A cross-sectional and a double-blind, placebo-controlled trial. Atherosclerosis 166: 379-386, 2003.
51. Kvetny J, Heldgaard PE, Bladbjerg EM and Gram J: Subclinical hypothyroidism is associated with a low-grade inflammation, increased triglyceride levels and predicts cardiovascular disease in males below 50 years. Clin Endocrinol (Oxf) 61: 232-238, 2004.
52. Tuzcu A, Bahceci M, Gokalp D, Tuzun Y and Gunes K: Subclinical hypothyroidism may be associated with elevated high-sensitive c-reactive protein (low grade inflammation) and fasting hyperinsulinemia. Endocr J 52: 89-94, 2005.
53. Verma S, Li S-H, Badiwala MV, et al: Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation 105: 1890-1896, 2002.
54. Cai H and Harrison DG: Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 87: 840-844, 2000.
55. Lubos E, Handy DE and Loscalzo J: Role of oxidative stress and nitric oxide in atherothrombosis. Front Biosci 13: 5323-5344, 2008.
56. Higashi Y, Noma K, Yoshizumi M and Kihara Y: Endothelial function and oxidative stress in cardiovascular diseases. Circ J 73: 411-418, 2009.
57. Coria MJ, Pastran AI and Gimenez MS: Serum oxidative stress parameters of women with hypothyroidism. Acta Biomed 80: 135-139, 2009.
58. Torun AN, Kulaksizoglu S, Kulaksizoglu M, Pamuk BO, Isbilen E and Tutuncu NB: Serum total antioxidant status and lipid peroxidation marker malondialdehyde levels in overt and subclinical hypothyroidism. Clin Endocrinol (Oxf) 70: 469-474, 2009.
59. Cebeci E, Alibaz-Oner F, Usta M, Yurdakul S and Erguney M: Evaluation of oxidative stress, the activities of paraoxonase and arylesterase in patients with subclinical hypothyroidism. J Investig Med 60: 23-28, 2012.
60. Ozturk U, Vural P, Ozderya A, Karadag B, Dogru-Abbasoglu S and Uysal M: Oxidative stress parameters in serum and low density lipoproteins of Hashimoto's thyroiditis patients with subclinical and overt hypothyroidism. Int Immunopharmacol 14: 349-352, 2012.
61. G DX, J HP, H LS and L SZ: Alpha-lipoic acid improves endothelial dysfunction in patients with subclinical hypothyroidism. Exp Clin Endocrinol Diabetes 118: 625-629, 2010.
62. Fujii N, Tsuchihashi K, Sasao H, et al: Insulin resistance functionally limits endothelium-dependent coronary vasodilation in nondiabetic patients. Heart Vessels 23: 9-15, 2008.
63. Kim J-a, Montagnani M, Koh KK and Quon MJ: Reciprocal relationships between insulin resistance and endothelial dysfunction molecular and pathophysiological mechanisms. Circulation 113: 1888-1904, 2006.
64. Gen R, Akbay E and Sezer K: Insulin resistance and cardiovascular risk factors in patients with mild and severe subclinical hypothyroidism. The Endocrinologist 20: 128-130, 2010.
65. Maratou E, Hadjidakis DJ, Kollias A, et al: Studies of insulin resistance in patients with clinical and subclinical hypothyroidism. Eur J Endocrinol 160: 785-790, 2009.
66. Al Sayed A, Al Ali N and Alfadhli E: Subclinical hypothyroidism is associated with early insulin resistance in Kuwaiti women. Endocr J 53: 653-657, 2006.
67. Peeters RP, Van Der Deure WM, Van Den Beld AW, et al: The Asp727Glu polymorphism in the TSH receptor is associated with insulin resistance in healthy elderly men. Clin Endocrinol (Oxf) 66: 808-815, 2007.
68. Taddei S, Caraccio N, Virdis A, et al: Impaired endothelium-dependent vasodilatation in subclinical hypothyroidism: beneficial effect of levothyroxine therapy. J Clin Endocrinol Metab 88: 3731-3737, 2003.
69. Monzani F, Caraccio N, Kozakowa M, et al: Effect of levothyroxine replacement on lipid profile and intima-media thickness in subclinical hypothyroidism: a double-blind, placebo-controlled study. J Clin Endocrinol Metab 89: 2099-2106, 2004.
70. Oner FA, Yurdakul S, Oner E, Uzum AK and Erguney M: Evaluation of the effect of L-thyroxin therapy on endothelial functions in patients with subclinical hypothyroidism. Endocrine 40: 280-284, 2011.
71. Razvi S, Ingoe L, Keeka G, Oates C, McMillan C and Weaver JU: The beneficial effect of L-thyroxine on cardiovascular risk factors, endothelial function, and quality of life in subclinical hypothyroidism: randomized, crossover trial. J Clin Endocrinol Metab 92: 1715-1723, 2007.
72. Adrees M, Gibney J, El-Saeity N and Boran G: Effects of 18 months of l-T4 replacement in women with subclinical hypothyroidism. Clin Endocrinol (Oxf) 71: 298-303, 2009.
73. Cabral MD, Teixeira P, Soares D, Leite S, Salles E and Waisman M: Effects of thyroxine replacement on endothelial function and carotid artery intima-media thickness in female patients with mild subclinical hypothyroidism. Clinics (Sao Paulo) 66: 1321-1328, 2011.
74. Pasqualetti G, Tognini S, Polini A, Caraccio N and Monzani F: Is subclinical hypothyroidism a cardiovascular risk factor in the elderly? J Clin Endocrinol Metab 98: 2256-2266, 2013.
75. Razvi S, Weaver JU, Butler TJ and Pearce SH: Levothyroxine treatment of subclinical hypothyroidism, fatal and nonfatal cardiovascular events, and mortality. Arch Intern Med 178: 811-817, 2012.
76. Cooper DS: Clinical practice. Subclinical hypothyroidism. N Engl J Med 345: 260-265, 2001.